Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Dynamic MRI Lesion Evolution in Pediatric Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Multiple Sclerosis
S27 - MS Neuroimaging (2:00 PM-2:12 PM)
006
In Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD), both radiological lag with worsening of the MRI during clinical recovery and dramatic lesion resolutions have been reported. There are few studies studying lesion evolution in pediatric MOGAD.

To evaluate MRI lesion evolution over time and correlate with patients’ clinical state.

Clinical and paraclinical features were reviewed in children (<18yr) with MOGAD from five UK tertiary paediatric neurosciences centres between 2014-2022.

 558 MRI scans from 152 patients and 295 attacks were available for analysis. Median age at presentation was 6.1yrs (IQR 4.0-10.6), 64 (42.1%) were male and 41 (26.9%) were of non-White ethnicities. At final follow-up (median period 4.42 years, IQR: 2.28-7.74) 57/152 (37.5%) had a relapsing disease course. Median number of relapses were 3, IQR (2-4). At onset, brain lesions were seen in 84/152 (55.2%), spine in 31/152 (20.3%), optic nerve in 48/152 (31.5%) and gadolinium-enhancing lesions in 34/42 (80.9%). MRI was normal in 8/152(5.2%) at first scan, of which 4/8 had new asymptomatic lesions within 1 month. New asymptomatic lesions (> 1 month) following first clinical event were seen in 17/152 (11.1%) with persistent contrast enhancement in 8/49 (16.3%). Of 89 patients who had follow-up imaging following first attack, 16 relapsed within 6 months, complete lesion resolution was reported in 26/89 (17.5%) (22 monophasic, 4 relapsing) following 1st acute attack, 7/35(20%) after 2nd acute attack, and 1/16 (6.2%) following 3rd acute attack and none following further relapses. Partial resolution of MRI lesions was seen in 19/51 (37.2%) monophasic patients and 9/39(23%) relapsing patients after the first follow-up scan (p>0.5).

Lesions in paediatric MOGAD are dynamic and timing of MRI scanning may reveal different regional involvement. Unlike in MS, a significant number of MOGAD patients will have complete lesion resolution at first follow-up, although this repair ability is reduced in relapsing patients.

Authors/Disclosures
Omar Abdel-Mannan, MD (Great Ormond Street Hospital)
PRESENTER
Dr. Abdel-Mannan has nothing to disclose.
Dimitrios Champsas, MBBS (Institue of Neurology, UCL) Dr. Champsas has nothing to disclose.
Sharmila Manivannan, MD,MBBS,Other Dr. Manivannan has nothing to disclose.
Kshitij Mankad Kshitij Mankad has nothing to disclose.
Rachel Kneen, MD Dr. Kneen has nothing to disclose.
Vivek Chitre, MD (Cambridge university hospitals NHS Foundation Trust) Dr. Chitre has nothing to disclose.
Sukhvir Wright No disclosure on file
Evangeline Wassmer, MD (Birmingham Children's Hospital) Dr. Wassmer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Wassmer has received research support from Birmingham Children's Hospital Charity Research Foundation.
Cheryl Hemingway The institution of Cheryl Hemingway has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. The institution of Cheryl Hemingway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. The institution of Cheryl Hemingway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Cheryl Hemingway has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Cheryl Hemingway has received research support from Medical research Committee.
Thomas Rossor, PhD,MBBS (Evelina London Children's Hospital) Dr. Rossor has nothing to disclose.
Ming Lim Ming Lim has nothing to disclose.
Olga Ciccarelli, MD, PhD, FRCP (UCL Institute of Neurology) Prof. Ciccarelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Ciccarelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Prof. Ciccarelli has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Prof. Ciccarelli has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEUROLOGY Journal.
Yael Hacohen, MBBS (Great Ormond Street Hospital) Dr. Hacohen has nothing to disclose.